Lung cancer in 2017

Giant steps and stumbling blocks

In 2017, major advances in the treatment of non-small-cell lung cancer (NSCLC) continued to emanate from the fields of molecularly targeted therapy and immunotherapy. In the former, new drugs with improved efficacy and reduced toxicity entered the clinic; in the latter, immune-checkpoint inhibition proved efficacious after chemoradiotherapy for stage III disease, but had disparate results in the frontline treatment of stage IV disease.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Thomas, A., Liu, S. V., Subramaniam, D. S. & Giaccone, G. Refining the treatment of NSCLC according to histological and molecular subtypes. Nat. Rev. Clin. Oncol. 12, 511–526 (2015).

    CAS  Article  PubMed  Google Scholar 

  2. 2

    Mok, T. S. et al. Osimertinib or platinum–pemetrexed in EGFR T790M-positive lung cancer. N. Engl. J. Med. 376, 629–640 (2017).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  3. 3

    Ramalingam, S. et al. Osimertinib versus standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA. Ann. Oncol. 28 (Suppl. 5), v605–v649 (2017).

    Google Scholar 

  4. 4

    Heigener, D. F. & Reck, M. Crizotinib. Recent Results Cancer Res. 201, 197–205 (2014).

    CAS  Article  PubMed  Google Scholar 

  5. 5

    Tang, S. C. et al. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Int. J. Cancer 134, 1484–1494 (2014).

    Article  PubMed  PubMed Central  Google Scholar 

  6. 6

    Peters, S. et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N. Engl. J. Med. 377, 829–838 (2017).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  7. 7

    Hida, T. et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet 390, 29–39 (2017).

    CAS  Article  Google Scholar 

  8. 8

    Carbone, D. P. et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N. Engl. J. Med. 376, 2415–2426 (2017).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  9. 9

    Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1–positive non-small-cell lung cancer. N. Engl. J. Med. 375, 1823–1833 (2016).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  10. 10

    Antonia, S. J. et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1709937 (2017).

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to David F. Heigener.

Ethics declarations

Competing interests

D.F.H. and M.R. are advisory board members for, and have received honoraria for speaking and reimbursement for travel from Astra Zeneca, BMS, Boehringer Ingelheim, Lilly, MSD, Pfizer, and Roche. Both authors have also received honoraria for speaking from Chugai and Fresenius; D.F.H. is an advisory board member for both companies, and M.R. for Chugai.

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Heigener, D., Reck, M. Giant steps and stumbling blocks. Nat Rev Clin Oncol 15, 71–72 (2018). https://doi.org/10.1038/nrclinonc.2017.178

Download citation

Further reading

Search

Quick links

Sign up for the Nature Briefing newsletter for a daily update on COVID-19 science.
Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing